Advent International awarded Colcapital´s recognition by its value creation impact on Grupo Biotoscana

Montevideo, Uruguay, October 24th 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that Advent International, a key shareholder, was recognized for its outstanding impact on value creation at GBT-Grupo Biotoscana, not only in Colombia, but in the Latin-American region.

Colcapital (Colombian Association of Private Equity Funds), in partnership with Deloitte, organized an event to award private equity firms that have demonstrated how the industry contributes to the development of the Colombian economy. The event included four different award categories, and Advent International was recognized with the “Greater impact generated in companies” award.

Following Advent´s entry as a strategic partner at GBT-Grupo Biotoscana in 2011, GBT has grown into a true pan-regional player through three acquisitions since its investment. In July GBT priced its initial public offering generating proceeds of US$ 375.2 million. This was the largest healthcare IPO in Latin America since 2011 and the largest healthcare IPO in the Americas this year so far. Advent´s recognition at ColCapital´s awards, highlights the generation of value through an integrated strategy and execution, including a clear long-term vision, the implementation of excellent corporate governance practices, a successful internationalization process, both organic and through M&A, disciplined product innovation and introduction practices, rigorous post-merger integration execution, amongst others

“We are pleased to receive this recognition, which highlights the impact that Advent´s commitment in terms of vision, constant support and deployment of resources, combined with a strong management team can have on the results of a company” said Mauricio Salgar, Managing Director of Advent International in Bogota.

GBT is one of the few Latin American integrated pharmaceutical companies engaged primarily in the development, manufacturing and commercialization of branded specialty pharmaceutical products throughout the region. GBT has an established presence in all major Latin American markets, with operations in Brazil, Argentina, Colombia, Bolivia, Chile, Ecuador, Mexico, Paraguay, Peru and Uruguay.

See the full article.

About GBT
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products.

To find out more about Grupo Biotoscana, please go to

About Advent International
Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 325 private equity transactions in 41 countries and as of March 31, 2017, it had $39 billion in assets under management. With offices on four continents, Advent has established a globally integrated team of 190 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom. After more than 30 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies.